

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

205834Orig1s000

STATISTICAL REVIEW(S)



U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Translational Sciences
Office of Biostatistics

STATISTICAL REVIEW AND EVALUATION

CLINICAL STUDIES

NDA #: 205834
Supplement #: 0000
Drug Name: Sofosbuvir and Ledipasvir fixed-dose combination
Indication(s): Treatment of chronic hepatitis C for adults
Applicant: Gilead Sciences, Inc.
Date(s): Original NDA Submitted Date: February 10, 2014
PDUFA date: October 10, 2014
Review Priority: Priority

Biometrics Division: DB4
Statistical Reviewer: Karen Qi, Ph.D.
Concurring Reviewers: Fraser Smith, Ph.D.
Medical Division: Antiviral
Clinical Team: Sarah Connelly, MD
Project Manager: Linda Onaga, M.P.H.

Keywords:

one-sample binomial test, Clopper-Person exact confidence interval, Zelen's exact test, stratified Cochran-Mantel-Haenszel test, exact confident interval based on inverting a two-sided test, hepatitis C

Table of Contents

1	EXECUTIVE SUMMARY	5
2	INTRODUCTION	6
2.1	OVERVIEW.....	6
2.2	DATA SOURCES	7
3	STATISTICAL EVALUATION	7
3.1	DATA AND ANALYSIS QUALITY	7
3.2	EVALUATION OF EFFICACY	8
3.2.1	<i>ION-1 and ION-3</i>	8
3.2.2	<i>ION-2</i>	18
3.3	EVALUATION OF SAFETY	25
4	FINDINGS IN SPECIAL/SUBGROUP POPULATIONS	25
4.1	SUBGROUP ANALYSES FOR SVR12 RATE.....	25
4.1.1	<i>Gender, Race, Age, and Geographic Region</i>	25
4.1.2	<i>Baseline Characteristics</i>	26
4.2	SUBGROUP ANALYSES FOR RELAPSE RATE	26
4.2.1	<i>Subgroup Analyses for Relapse Rate in TN Subjects in ION-3 Study</i>	26
4.2.2	<i>Subgroup Analyses for Relapse Rate in TE Subjects in ION-2 Study</i>	31
5	SUMMARY AND CONCLUSIONS	36
5.1	STATISTICAL ISSUES	36
5.2	COLLECTIVE EVIDENCE.....	36
5.3	CONCLUSIONS AND RECOMMENDATIONS	37
6	APPENDICES.....	38

LIST OF TABLES

Table 1: List of Studies Reviewed in Report.....	7
Table 2: Patient Disposition in ION-1 and ION-3	12
Table 3: Patient Demographics and Baseline HCV Disease Characteristics in ION-1 and ION-3 (All Treated).....	13
Table 4: Applicant’s Results for Primary Efficacy Endpoint of SVR12 Rate in ION-1 and ION-3 (All Treated).....	14
Table 5: Applicant’s Results for Inter Group Comparison of SVR12 Rates in ION-3 (All Treated).....	14
Table 6: Reviewer’s Results for Primary Efficacy Endpoint of SVR12 Rate in ION-1 and ION-3 (All Treated).....	15
Table 7: Reviewer’s Results for Inter Group Comparison of SVR12 Rates in ION-3 (All Treated)	15
Table 8: Reviewer’s Results for Relapse Rates in ION-1 and ION-3 (All Treated).....	16
Table 9: Reviewer’s Results for SVR Rates in ION-1 and ION-3 (All Treated).....	17
Table 10: Applicant’s Results for Concordance between SVR12 and SVR12 in Part A of ION-1 (All Treated).....	17
Table 11: Reviewer’s Results for Comparison of Relapse Rates Between Different Treatment Durations in ION-3 (All Treated).....	18
Table 12: Patient Disposition in ION-2	19
Table 13: Applicant’s Results for Demographics and Baseline Characteristics in ION-2 (All Treated).....	20
Table 14: Applicant’s Results for Primary Efficacy Endpoint of SVR12 Rate in ION-2 (All Treated).....	22
Table 15: Reviewer’s Results for Relapse Rates in ION-2 (All Treated).....	23
Table 16: Reviewer’s Results for SVR Rates in ION-2 (All Treated).....	23
Table 17: Applicant’s Results for Concordance between SVR12 and SVR12 in ION-2 (All Treated).....	23
Table 18: Reviewer’s Results for SVR12 and Relapse Rates in ION-2 (All Treated).....	24
Table 19: Reviewer’s Results for Comparison of Relapse Rates between Different Treatment Durations in ION-2 (All Treated).....	25
Table 20: Reviewer’s Results for Subgroup Relapse Rates for 8-Week Treatment Arms in ION-3 (All Treated).....	27
Table 21: Reviewer’s Results for Relapse Rates by Baseline Viral Load for 8-Week and 12-Week Regimens in ION-3 (All Treated).....	28
Table 22: Reviewer’s Results for Subgroup Relapse Rates for 8-Week and 12-Week Regimens in ION-3 (All Treated).....	29
Table 23: Reviewer’s Results for Relapse Rates by Early Viral Response with Positive Predictive Values and Negative Predictive Values in ION-3 (All Treated).....	30
Table 24: Reviewer’s Results for Relapse Rates by Early Viral Response in ION-3 (All Treated).....	31
Table 25: Reviewer’s Results for Subgroup Relapse Rate in ION-2 (All Treated).....	31
Table 26: Reviewer’s Results for Subgroup Relapse Rates for 8-Week and 12-Week Regimens in ION-2 (All Treated).....	33
Table 27: Reviewer’s Results for Relapse Rates by Early Viral Response with Positive Predictive Values and Negative Predictive Values in ION-3 (All Treated).....	34
Table 28: Reviewer’s Results for Relapse Rates by Early Viral Response for All Subjects in ION-2 (All Treated).....	35
Table 29: Reviewer’s Results for Relapse Rates by Early Viral Response for Cirrhotic Subjects in ION-2 (All Treated).....	35
Table 30: Reviewer’s Results for Relapse Rates by Early Viral Response for Non-Cirrhotic Subjects in ION-2 (All Treated).....	36
Table 31: Reviewer’s Results for SVR12 Rates by Demographics in ION-1 and ION-3 (All Treated).....	38
Table 32: Reviewer’s Results for SVR12 Rates by Baseline Characteristics in ION-1 and ION-3 (All Treated).....	39
Table 33: Reviewer’s Results for SVR12 Rates by Demographics in ION-2 (All Treated).....	40
Table 34: Reviewer’s Results for SVR12 Rates by Baseline Characteristics in ION-2 (All Treated).....	41

LIST OF FIGURES

Figure 1: Reviewer's Results for On-Treatment Virologic Response by Treatment Groups in ION-1 and ION-3 (All Treated, NC=F).....	16
Figure 2: Reviewer's Results for On-Treatment Virologic Response by Treatment Groups in ION-2 (All Treated, NC=F).....	22

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.